AvertD is “an innovative genetic risk assessment test” that utilizes genes associated with the brain’s reward pathways and addiction to assess the
genetic susceptibility to opioids
ACSH relies on donors like you. If you enjoy our work, please contribute.
Make your tax-deductible gift today!